

Philip D Home Dm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/89850/publications.pdf>

Version: 2024-02-01

184
papers

12,774
citations

61687

45
h-index

27587

110
g-index

188
all docs

188
docs citations

188
times ranked

13160
citing authors

#	ARTICLE	IF	CITATIONS
1	Tackling obesity during the COVID-19 pandemic. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3393.	1.7	2
2	The evolution of insulin therapy. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108816.	1.1	24
3	Can we find out if COVID-19 causes diabetes?. <i>British Journal of Diabetes</i> , 2021, 21, 1-2.	0.1	1
4	Heart failure management; a perspective from diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2021, 176, 108849.	1.1	1
5	Efficacy and safety of iGlarLixi versus IDegAsp : Results of a systematic literature review and indirect treatment comparison. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2660-2669.	2.2	7
6	Insulin therapy development beyond 100 years. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 695-707.	5.5	14
7	Future directions in insulin therapy. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154889.	1.5	4
8	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
9	Is Insulin Therapy Safe?. <i>American Journal of Therapeutics</i> , 2020, 27, e106-e114.	0.5	3
10	Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 2509-2518.	4.3	33
11	Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2179-2188.	2.2	14
12	Comparison of Multiple Cut Points for Time in Range in Relation to Risk of Abnormal Carotid Intima-Media Thickness and Diabetic Retinopathy. <i>Diabetes Care</i> , 2020, 43, e99-e101.	4.3	21
13	Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2170-2178.	2.2	11
14	How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?. <i>Diabetes Care</i> , 2020, 43, 272-274.	4.3	2
15	Hypoglycaemia risk with insulin glargine 300 µU/mL compared with glargine 100 µU/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1664-1669.	2.2	5
16	Letter to the Editor in Response to article: "Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.)". <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 417.	1.8	4
17	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground. <i>Diabetes Care</i> , 2019, 42, 1615-1623.	4.3	8
18	The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 424-427.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Meal-timeâ€”+â€”basal insulin therapy: Is all not well?. Diabetes Research and Clinical Practice, 2019, 157, 107923.	1.1	0
20	Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia, 2019, 62, 357-369.	2.9	67
21	Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%. Diabetes, Obesity and Metabolism, 2019, 21, 321-329.	2.2	15
22	Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technology and Therapeutics, 2018, 20, 160-170.	2.4	20
23	Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655â€”662. Diabetes Care, 2018, 41, e64-e64.	4.3	3
24	Glycaemic control and hypoglycaemia during 12â€”months of randomized treatment with insulin glargine 300â€”U/mL versus glargine 100â€”U/mL in people with type 1 diabetes (<sc>EDITION</sc> 4). Diabetes, Obesity and Metabolism, 2018, 20, 121-128.	2.2	34
25	A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 138, 253-261.	1.1	13
26	Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. Diabetes, Obesity and Metabolism, 2018, 20, 921-929.	2.2	5
27	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. Diabetes, Obesity and Metabolism, 2018, 20, 2229-2237.	2.2	7
28	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. Diabetes, Obesity and Metabolism, 2018, 20, 2220-2228.	2.2	5
29	2020 vision â€” An overview of prospects for diabetes management and prevention in the next decade. Diabetes Research and Clinical Practice, 2018, 143, 101-112.	1.1	33
30	Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM). Diabetes, 2018, 67, 1073-P.	0.3	5
31	A diabetes mellitus guideline gone wrong â€” the 2017 ACP update. Nature Reviews Endocrinology, 2017, 13, 191-192.	4.3	2
32	Comment on Pathak et al. Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005â€”2011. Diabetes Care 2016;39:363â€”370. Diabetes Care, 2017, 40, e25-e25.	4.3	1
33	Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action. Clinical Therapeutics, 2017, 39, 1064-1076.	1.1	40
34	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology and Therapeutics, 2017, 19, 391-399.	2.4	45
35	Comment on Abd El Aziz et al., A metaâ€”analysis comparing clinical effects of shortâ€”or longâ€”acting <sc>GLP</sc>â€”1 receptor agonists versus insulin treatment from headâ€”toâ€”head studies in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2017, 19, 304-305.	2.2	1
36	George Alberti: A Myriad of Contributions to Diabetes and Beyond. Diabetes Care, 2017, 40, 1154-1158.	4.3	1

#	ARTICLE	IF	CITATIONS
37	Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study. <i>Diabetes Research and Clinical Practice</i> , 2017, 133, 150-158.	1.1	6
38	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. <i>Diabetes Research and Clinical Practice</i> , 2017, 131, 49-60.	1.1	26
39	IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 103-111.	1.2	4
40	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. <i>Diabetes Care</i> , 2016, 39, S187-S195.	4.3	42
41	Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300â€‰U/mL in People with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 252-257.	2.4	42
42	Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1011-1020.	2.2	73
43	Biosimilar insulins: guidance for data interpretation by clinicians and users. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 911-918.	2.2	24
44	An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 510-526.	2.4	30
45	Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 432-440.	1.1	30
46	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). <i>Diabetes Care</i> , 2015, 38, 2217-2225.	4.3	183
47	Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation. <i>Diabetes Care</i> , 2015, 38, 105-112.	4.3	41
48	An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes. <i>Journal of Medical Economics</i> , 2015, 18, 230-240.	1.0	17
49	Cancer and bone fractures in observational follow-up of the RECORD study. <i>Acta Diabetologica</i> , 2015, 52, 539-546.	1.2	13
50	Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 350-359.	1.1	22
51	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2015, 38, 1567-1582.	4.3	180
52	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. <i>Diabetes Care</i> , 2015, 38, 1627-1633.	4.3	28
53	Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?. <i>Diabetes Care</i> , 2015, 38, 2234-2236.	4.3	14
54	Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1â€‰year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 179-187.	2.2	81

#	ARTICLE	IF	CITATIONS
55	Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 15-22.	2.2	21
56	Response to Comment on Home et al. Predictive and Explanatory Factors of Change in HbA 1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. <i>Diabetes Care</i> 2014;37:1237-1245. <i>Diabetes Care</i> , 2014, 37, e184-e184.	4.3	0
57	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). <i>Diabetes Care</i> , 2014, 37, 2755-2762.	4.3	302
58	The vexed question of hypoglycaemia and health economics. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 289-293.	2.2	1
59	Impact of Biosimilar Insulins on Clinical Practice. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 179-185.	1.3	10
60	Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A1chieve Study. <i>Diabetes Therapy</i> , 2014, 5, 113-126.	1.2	1
61	An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 319-327.	1.1	17
62	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.	4.3	58
63	Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. <i>Diabetes Care</i> , 2014, 37, 1237-1245.	4.3	30
64	Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?. <i>Diabetes Care</i> , 2014, 37, 1499-1508.	4.3	122
65	Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. <i>Diabetes Care</i> , 2014, 37, 2108-2113.	4.3	63
66	Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western Countries. <i>Diabetes Therapy</i> , 2013, 4, 91-102.	1.2	28
67	Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. <i>Diabetes Care</i> , 2013, 36, 2489-2496.	4.3	261
68	The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: Results from the A1chieve observational study. <i>Diabetes Research and Clinical Practice</i> , 2013, 101, 326-332.	1.1	1
69	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
70	Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct. <i>American Heart Journal</i> , 2013, 166, 208-216.e28.	1.2	23
71	Biphasic Insulin Aspart 30 in Insulin-Naive People with Type 2 Diabetes in Non-western Nations: Results from a Regional Comparative Multinational Observational Study (A1chieve). <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 954-963.	2.4	3
72	Results of a reevaluation of cardiovascular outcomes in the RECORD trial. <i>American Heart Journal</i> , 2013, 166, 240-249.e1.	1.2	149

#	ARTICLE	IF	CITATIONS
73	Observational research: an integral part of enhancing diabetes management in south-east Asia. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, S1-S2.	1.1	0
74	Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2012;35:2140-2147. <i>Diabetes Care</i> , 2013, 36, e106-e106.	4.3	2
75	Insulin Therapy and Cancer. <i>Diabetes Care</i> , 2013, 36, S240-S244.	4.3	35
76	Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations. <i>Diabetes Care</i> , 2013, 36, 3361-3367.	4.3	13
77	Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy. <i>Obstetrics and Gynecology International</i> , 2012, 2012, 1-11.	0.5	61
78	Improving health outcomes in 2011 for people with type 2 diabetes: A report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 8-12 December 2011. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 101-108.	0.6	0
79	(20) Improved cardiovascular outcomes with dpp-4 inhibitors in diabetes - a meta-analysis. <i>Atherosclerosis</i> , 2012, 223, 533.	0.4	1
80	Cardiovascular Disease and Oral Agent Glucose-Lowering Therapies in the Management of Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, S-33-S-42.	2.4	12
81	Observational Study of the Association of First Insulin Type in Uncontrolled Type 2 Diabetes with Macrovascular and Microvascular Disease. <i>PLoS ONE</i> , 2012, 7, e49908.	1.1	7
82	Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 305-313.	0.9	15
83	The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 780-788.	2.2	168
84	Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2012, 29, 716-720.	1.2	31
85	An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. <i>Diabetes Research and Clinical Practice</i> , 2011, 94, 352-363.	1.1	134
86	Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2011, 4, 23.	1.1	67
87	Hypoglycemia Rates with Basal Insulin Analogs. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, S-53-S-64.	2.4	60
88	Safety of PPAR Agonists. <i>Diabetes Care</i> , 2011, 34, S215-S219.	4.3	26
89	Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes. <i>Diabetes Care</i> , 2011, 34, 1394-1396.	4.3	28
90	Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. <i>Diabetes Care</i> , 2011, 34, 661-665.	4.3	156

#	ARTICLE	IF	CITATIONS
91	Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance. Evidence-Based Medicine, 2011, 16, 10-11.	0.6	0
92	The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Current Cardiology Reviews, 2010, 6, 82-90.	0.6	337
93	Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A) Tj ETQq1 1 0.784314 rgBT /Over	2.9	147
94	Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes, Obesity and Metabolism, 2010, 12, 772-779.	2.2	89
95	Endothelial Progenitor Cells in Subclinical Hypothyroidism: The Effect of Thyroid Hormone Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 319-322.	1.8	41
96	Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. European Heart Journal, 2010, 31, 824-831.	1.0	203
97	Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Current Medical Research and Opinion, 2010, 26, 1621-1628.	0.9	21
98	Lipoprotein associations with endothelial dysfunction and carotid intima-media thickness in young people with Type 1 diabetes. Atherosclerosis, 2010, 213, e2-e3.	0.4	0
99	How can observational trials inform and improve clinical practice?. Diabetes Research and Clinical Practice, 2010, 88, S1-S2.	1.1	6
100	Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Research and Clinical Practice, 2010, 88, S3-S9.	1.1	117
101	Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime) Tj ETQq1 1 0.784314 rgBT /Overl	4.3	112
102	Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia, 2009, 52, 2499-2506.	2.9	136
103	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, The, 2009, 373, 2125-2135.	6.3	1,243
104	Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovascular Diabetology, 2008, 7, 10.	2.7	38
105	Injection site abscesses. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 104-104.	0.2	1
106	Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes, Obesity and Metabolism, 2008, 10, 699-718.	2.2	48
107	HbA _{1c} : the case for using estimated average glucose (eAG). Diabetic Medicine, 2008, 25, 895-898.	1.2	2
108	Treatment Satisfaction and Quality of Life With Insulin Glargine Plus Insulin Lispro Compared With NPH Insulin Plus Unmodified Human Insulin in Individuals With Type 1 Diabetes. Diabetes Care, 2008, 31, 1112-1117.	4.3	81

#	ARTICLE	IF	CITATIONS
109	Management of type 2 diabetes: summary of updated NICE guidance. <i>BMJ: British Medical Journal</i> , 2008, 336, 1306-1308.	2.4	94
110	Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. <i>New England Journal of Medicine</i> , 2007, 357, 28-38.	13.9	729
111	Medical training in the UK: sleepwalking to disaster. <i>Lancet, The</i> , 2007, 369, 1673-1675.	6.3	3
112	A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone+metformin therapy when starting insulin therapy in people with Type 2 diabetes. <i>Diabetic Medicine</i> , 2007, 24, 618-625.	1.2	21
113	Insulin detemir: from concept to clinical experience. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 325-343.	0.9	120
114	Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2006, 71, 131-139.	1.1	31
115	The diabetes epidemic and the developing world. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2006, 23, 325-326.	0.2	1
116	Cardiovascular Risk Factors Predicting the Development of Distal Symmetrical Polyneuropathy in People with Type 1 Diabetes: A 9-Year Follow-up Study. <i>Annals of the New York Academy of Sciences</i> , 2006, 1084, 304-318.	1.8	9
117	Predicting the Development of Macrovascular Disease in People with Type 1 Diabetes: A 9-Year Follow-up Study. <i>Annals of the New York Academy of Sciences</i> , 2006, 1084, 191-207.	1.8	10
118	A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 1269-1274.	4.3	605
119	Guidelines for the treatment and management of new-onset diabetes after transplantation1.. <i>Clinical Transplantation</i> , 2005, 19, 291-298.	0.8	228
120	A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 545-553.	1.7	58
121	Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. <i>Diabetologia</i> , 2005, 48, 1726-1735.	2.9	143
122	Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2005, 21, 989-998.	0.9	67
123	Principles for National and Regional Guidelines on Cardiovascular Disease Prevention. <i>Circulation</i> , 2004, 109, 3112-3121.	1.6	314
124	Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial. <i>Diabetes Care</i> , 2004, 27, 1081-1087.	4.3	253
125	Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. <i>European Journal of Internal Medicine</i> , 2004, 15, 496-502.	1.0	91
126	Issues relating to the early or earlier use of insulin in type 2 diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2003, 20, 63-71.	0.2	34

#	ARTICLE	IF	CITATIONS
127	The challenge of poorly controlled diabetes mellitus. <i>Diabetes and Metabolism</i> , 2003, 29, 101-109.	1.4	30
128	Review: Rosiglitazone or pioglitazone as add-on therapy is effective for glycemic control in type 2 diabetes. <i>ACP Journal Club</i> , 2003, 139, 67.	0.1	0
129	Immune Responses to Insulin Aspart and Biphasic Insulin Aspart in People With Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 876-882.	4.3	101
130	Considerations on blood glucose management in Type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 273-285.	1.7	9
131	An overview of insulin glargine. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, S57-S63.	1.7	28
132	Interval between insulin injection and meal in relation to glycated haemoglobin. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, 51-56.	0.2	11
133	Insulin glargine: the first clinically useful extended-action insulin analogue. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 1891-1902.	0.9	13
134	Postprandial hyperglycaemia: mechanisms and importance. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, S7-S11.	2.2	1
135	Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. <i>Diabetic Medicine</i> , 2000, 17, 762-770.	1.2	223
136	Insulin Glargine. <i>Drugs</i> , 2000, 59, 261-262.	4.9	1
137	Insulin glargine: the first clinically useful extended-acting insulin in half a century?. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 307-314.	1.9	30
138	“Things that most changed my practice in 1998”™. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1999, 16, 93-94.	0.2	0
139	Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1999, 55, 199-203.	0.8	137
140	Insulin Aspart. <i>Drugs</i> , 1999, 57, 766-767.	4.9	1
141	Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. <i>Diabetes Care</i> , 1998, 21, 1904-1909.	4.3	219
142	Insulin resistance is not central to the burden of diabetes. , 1997, 13, 87-92.		5
143	The mission of St Vincent: Quality in European diabetes care. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1996, 13, 40-40.	0.2	0
144	The contribution of proinsulin and des-31,32 proinsulin to the hyperinsulinemia of diabetic and nondiabetic cirrhotic patients. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 254-260.	1.5	15

#	ARTICLE	IF	CITATIONS
145	A World of Diabetes: All Our Problem. <i>Diabetic Medicine</i> , 1995, 12, 289-290.	1.2	0
146	Pharmacoeconomics of Diabetes Surveillance and Detection Programmes. <i>Pharmacoeconomics</i> , 1995, 8, 72-79.	1.7	0
147	Databases and Diabetes: Dogsbodies or Devils?. <i>Diabetic Medicine</i> , 1993, 10, 303-304.	1.2	1
148	Twenty-four hour C-peptide and insulin secretion rates and diurnal profiles of glucose, lipids and intermediary metabolites in cirrhosis. <i>Clinical Science</i> , 1992, 83, 597-605.	1.8	14
149	A Depressing Problem. <i>Diabetic Medicine</i> , 1992, 9, 285-285.	1.2	0
150	Ownership. Communication and Teams. <i>Diabetic Medicine</i> , 1992, 9, 669-669.	1.2	0
151	Diabetic Medicine: Physiology of a Journal. <i>Diabetic Medicine</i> , 1992, 9, 7-8.	1.2	2
152	A Difficult Task. <i>Diabetic Medicine</i> , 1991, 8, 585-585.	1.2	0
153	Diabetes and the Number Revolution. <i>Diabetic Medicine</i> , 1991, 8, 400-401.	1.2	6
154	Human Insulin Gone Wrong?. <i>Diabetic Medicine</i> , 1991, 8, 799-799.	1.2	4
155	Language and Learning in Diabetes Care. <i>Diabetic Medicine</i> , 1991, 8, 504-504.	1.2	3
156	Editorial: Diabetes with a European Prospective. <i>Diabetic Medicine</i> , 1991, 8, 973-973.	1.2	1
157	Target: Diabetes. <i>Diabetic Medicine</i> , 1991, 8, 896-897.	1.2	0
158	The Most Important Diabetic Clinic. <i>Diabetic Medicine</i> , 1991, 8, 96-96.	1.2	2
159	Between the Devil and the Deep Blue Hypo. <i>Diabetic Medicine</i> , 1991, 8, 277-277.	1.2	1
160	Meetings, Meetings, the IDF, and the EASD. <i>Diabetic Medicine</i> , 1991, 8, 704-705.	1.2	0
161	Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. <i>Hepatology</i> , 1991, 14, 103-111.	3.6	135
162	Whose Diabetes Service is it, anyway?. <i>Diabetic Medicine</i> , 1990, 7, 549-549.	1.2	0

#	ARTICLE	IF	CITATIONS
163	EASD Growing Pains. Diabetic Medicine, 1990, 7, 8-9.	1.2	3
164	Editorial: Communicating with Patients. Diabetic Medicine, 1990, 7, 915-915.	1.2	0
165	Diabetes, the 1980s, and Beyond. Diabetic Medicine, 1990, 7, 97-98.	1.2	0
166	Power to the Case for Improving Diabetes Care. Diabetic Medicine, 1990, 7, 169-169.	1.2	0
167	COMAtose; or a Report on Sugar. Diabetic Medicine, 1990, 7, 197-198.	1.2	0
168	Glycosylated Haemoglobin Revisited. Diabetic Medicine, 1990, 7, 385-386.	1.2	3
169	Editorial: The Diabetes Team. Diabetic Medicine, 1989, 6, 357-357.	1.2	0
170	Replacing Insulin Injections. Diabetic Medicine, 1989, 6, 289-290.	1.2	2
171	Is it Time to Restructure Medical Training in Diabetes?. Diabetic Medicine, 1989, 6, 193-194.	1.2	0
172	Dangers for the Future of Diabetes Care?. Diabetic Medicine, 1989, 6, 101-102.	1.2	0
173	Towards the Ultimate Outcome. Diabetic Medicine, 1989, 6, 11-11.	1.2	3
174	Type 2 Diabetes and Reaven's Syndrome. Diabetic Medicine, 1989, 6, 559-560.	1.2	0
175	Success with the Young. Diabetic Medicine, 1989, 6, 633-633.	1.2	1
176	Diabetic Medicine. Diabetic Medicine, 1989, 6, 753-753.	1.2	0
177	The relationship between insulin sensitivity and skeletal muscle enzyme activities in hepatic cirrhosis. Hepatology, 1988, 8, 1615-1619.	3.6	85
178	Organizing diabetes care. Diabetic Medicine, 1988, 5, 681-681.	1.2	0
179	The OGTT: Gold that Does not Shine. Diabetic Medicine, 1988, 5, 313-314.	1.2	21
180	Driven to Abstraction. Diabetic Medicine, 1988, 5, 419-420.	1.2	1

#	ARTICLE	IF	CITATIONS
181	Spreading the Message. Diabetic Medicine, 1987, 4, 97-98.	1.2	1
182	5 The measurement of metabolite exchange across muscle beds. Bailliere's Clinical Endocrinology and Metabolism, 1987, 1, 863-878.	1.0	12
183	Focus "Diabetes" first, complications second. Diabetic Medicine, 1986, 3, 409-410.	1.2	1
184	Providing Motivation for better Diabetic Care. Diabetic Medicine, 1985, 2, 435-436.	1.2	1